by Matthew Shinkle
One of every four patients with a gynecologic oncology office visit had inadequate levels of cancer health literacy, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers found racial and ethnic … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Kalie VanDewater
Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.
“Although trial results inform policies … Read more
by Nicolas Wrigley
Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.… Read more
by Matthew Shinkle
Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.
Even among white women, the … Read more
by Mark L. Fuerst
Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.
In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more
by Jessica Nye, PhD
Left image: Eligibility and opportunity for participation in cancer clinical trials was found to be similar across race, level of disadvantage, and residential area. Source: Getty Images
Eligibility was not found to drive disparities in clinical … Read more
by Jordyn Sava
In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.Whether a patient with gynecologic cancer has insurance or is … Read more
by Ariana Pelosci
A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.
A recent single-institution study presented
by Jason Harris
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.1
Increasing the racial and ethnic diversity in
… Read moreby Vicki Moore, PhD
A recent study evaluated the effects programs aimed at addressing food insecurity have on treatment outcomes for patients with cancer. Each intervention seemed beneficial, with a voucher-plus-pantry program appearing to be the most effective. The study’s … Read more
by Coco Davis/ Fred Hutchinson Cancer Research Center
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy among women in the United States (US). Although the incidence rate is higher among White women, Black women have the lower survival … Read more
by Jonathan Goodman, MPhil
Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.
Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more
by Jon Kelvey
Black patients with ovarian cancer were less likely than their White counterparts to receive adjuvant chemotherapy after primary surgery, according to a study published in Gynecologic Oncology.
The study also showed that patients who did not undergo … Read more
by Sophia George
Providing equal access to care will not by itself equalize outcomes between Black and white women.
Women from the African diaspora are disproportionately affected by high-grade and aggressive ovarian tumours. In the United States, mortality due to … Read more
